Recent research highlighted the potential role of an atypical antipsychotic to treat anxiety a prevalent and undertreated symptom in BPD that comes without the typical metabolic side effects.
USA: Navacaprant, a new once-daily kappa opioid receptor antagonist, may cause a significant reduction of depression and anhedonia symptoms in participants with moderate-to-severe major depressive.
Efficacy of novel drug proven in MDD study europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.